Traditionally, immunohistochemical tumour biomarkers Ki-67, MCM2, and MCM3, CD138, p16 proteins that are known to be involved in cell proliferation have been used to elucidate histopathological features and clinical data of ameloblastoma Apart from Ki-67 that has been positively correlated with growth rate and shorter disease-free survival [23, 24] protein biomarkers have no significant association with clinical features of ameloblastoma [25]. Here, SDC1 is linked to neoplasm.